| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 01/19/2011 | EP2275104A2 Pharmaceutical and cosmetic composition including lactoferrin, ciclopirox and etidronic acid |
| 01/19/2011 | EP2275103A2 mTOR inhibitors in the treatment of endocrine tumors |
| 01/19/2011 | EP2275101A1 Polar lipid-rich fraction containing stearidonic acid and gamma linolenic acid from plant seeds and microbes, and its uses |
| 01/19/2011 | EP2275094A2 Reduction of intravenously administered nanoparticulate-formulation-induced adverse physiological reactions |
| 01/19/2011 | EP2275091A1 Pharmaceutical compositions comprising adsorbates of an amorphous drug |
| 01/19/2011 | EP2275075A2 Method of measuring an iron-saccharidic complex |
| 01/19/2011 | EP2274256A1 Polymorphisms predictive of platinum-coordinating compound-induced ototoxicity |
| 01/19/2011 | EP1933818B1 Methods and compositions using immunomodulatory compounds for the treatment of disorders associated with low plasma leptin levels |
| 01/19/2011 | EP1600507B1 Mutant SREBP-1c promoters and use thereof |
| 01/19/2011 | EP1587913B1 New strains of bifidobacterium having the ability to produce glutamine |
| 01/19/2011 | EP1547614B1 Medicinal composition for inhibiting the expression of atp-citrate lyase and use thereof |
| 01/19/2011 | EP1448995B1 Assay for screening candidate drugs for the treatment of inflammatory diseases |
| 01/19/2011 | EP1365808B1 Compositions for antitumour treatment containing ecteinascidin 743 |
| 01/19/2011 | EP1337234B1 Use of 2-oxothiazolidine 4-carboxylic acid derivatives as agents promoting skin peeling |
| 01/19/2011 | EP1252300B1 Nucleic acid molecules encoding transmembrane serine proteases, the encoded proteins and methods based thereon |
| 01/19/2011 | EP1185296B1 Prevention and treatment of amyloidogenic diseases |
| 01/19/2011 | CN1660081B Skin externally used paste |
| 01/19/2011 | CN101951922A Preparation for treating intestinal infection comprising oligosaccharides and insoluble cellular material |
| 01/19/2011 | CN101951900A Compositions comprising phytoestrogens selective for estrogen beta receptor and dietary fibres |
| 01/19/2011 | CN101948541A Compositions and methods for the diagnosis and treatment of tumor |
| 01/19/2011 | CN101948539A IL-18 binding proteins |
| 01/19/2011 | CN101947319A Medicinal composition for treating and preventing discomfort of people with myocardial ischemia |
| 01/19/2011 | CN101947223A Composite anesthetic, preparation method thereof, and use thereof in myocardial infarction animal model |
| 01/19/2011 | CN101507708B Preparation method of liposome |
| 01/19/2011 | CN101244067B Application of 23-hydroxyl radical betulic acid in preparing reversal agent multidrug resistance of cancer cell |
| 01/19/2011 | CN101237885B Agent for regeneration and/or protection of nerves |
| 01/18/2011 | US7872129 Nitrogen compounds such as (6-(3-Methylaminopropyl)-2-(2-tri-fluoromethylphenyl)pyrimidin-4-yl)-(1H -pyrazolo(3,4-b)pyridin-3-yl)-amine, use as glycogen synthase kinase-3 (GSK-3) antagonists |
| 01/18/2011 | US7872112 comprising rat apoptosis-specific eucaryotic initiation Factor-5A (eIF-5A),deoxyhypusine synthase (DHS) nucleic acids and polypeptides; human cytomegalovirus immediate-early promoter/enhancer |
| 01/18/2011 | US7872025 Optically active isomers of ketotifen and therapeutically active metabolites thereof |
| 01/18/2011 | US7871995 Drug delivery system comprising a tetrahydroxylated estrogen for use in hormonal contraception |
| 01/18/2011 | US7871994 at least one ingestion period preceding the permanent administration of hormone daily units has an ingestion pause in which either no daily units or units with a much lower hormone content is given |
| 01/18/2011 | US7871798 Mammalian cells that express VEGF-D polypeptides |
| 01/18/2011 | US7871786 Isolated nucleic acid encoding GEF-H1b polypeptide (Guanine nucleotide exchange factors); diagnosing abnormal cell proliferation and drug screening; measuring phosphorylation by p-21 activated kinase; antitumor agents, anticancer agents |
| 01/18/2011 | US7871765 Composition having antitumor effect |
| 01/18/2011 | US7871649 Antimicrobial compositions containing synergistic combinations of quaternary ammonium compounds and essential oils and/or constituents thereof |
| 01/18/2011 | US7871644 Mixture of drug, aminoacrylate polymer and acid |
| 01/18/2011 | US7871631 Inhibit inflammation for long periods without accompanying serious side effects in the drug therapy to patients with inflammatory bowel syndrome |
| 01/18/2011 | US7871630 Locally administering to tumor antigen-releasing agent, tumor leukocyte attractant and tumor interferon-gamma (IFN-g), and second type 1 inflammatory response-(IR1-)promoting agent for tumor therapy |
| 01/18/2011 | US7871618 Contact dermatitis, Drug induced delayed type cutaneous allergic reactions, Toxic epidermal necrolysis, Cutaneous T cell Lymphoma, Bullous pemphigoid, Alopecia aereata, Vitiligo, Acne Rosacea, Prurigo nodularis, Scleroderma, Herpes simplex virus; conjugated to polyoxyethylene glycol, serum albumin |
| 01/18/2011 | CA2637795C Antagonists of interleukin-15 |
| 01/18/2011 | CA2503274C Basic medicine-containing preparation |
| 01/18/2011 | CA2466642C Injectable depot composition |
| 01/18/2011 | CA2458797C Preparation and diabetic use of gibeberellins |
| 01/18/2011 | CA2441964C New pharmaceutical compositions based on anticholinergics and endothelin antagonists |
| 01/18/2011 | CA2372850C Synergistic combination comprising roflumilast and a pde-3 inhibitor |
| 01/18/2011 | CA2368637C Topical treatment or prevention of ocular infections |
| 01/18/2011 | CA2328073C Methods and compositions using cetirizine in combination with leukotriene inhibitors for treating conditions responsive to leukotriene inhibition |
| 01/18/2011 | CA2310534C Methods and compositions for treating primary and secondary tumors of the central nervous system (cns) |
| 01/18/2011 | CA2189055C Methods for modulating t cell responses by manipulating intracellular signal transduction |
| 01/13/2011 | WO2011006144A1 Methods of treating and preventing neurological disorders using docosahexaenoic acid |
| 01/13/2011 | WO2011005811A1 Combination therapy for the treatment of diabetes |
| 01/13/2011 | WO2011004882A1 Acid pump antagonist for treatment of diseases associated with abnormal gastrointestinal movement |
| 01/13/2011 | WO2011004843A1 Pharmaceutical composition for treatment of sirs or highly pathogenic influenza infection |
| 01/13/2011 | WO2011004379A1 Compositions and methods for treating cancer |
| 01/13/2011 | WO2011003191A1 Compositions and methods for enhancing virus efficacy |
| 01/13/2011 | WO2010102216A3 Enhancing coagulation or reducing fibrinolysis |
| 01/13/2011 | US20110009955 Compounds and method for coating surfaces in a hemocompatible manner |
| 01/13/2011 | US20110009631 Phenethanolamine Derivatives for Treatment of Respiratory Diseases |
| 01/13/2011 | US20110009484 Disinfectant and method of making |
| 01/13/2011 | US20110009481 Medicament for the treatment of viral skin and tumour diseases |
| 01/13/2011 | US20110009333 Pharmaceutical or cosmetic composition and use of a pkc inhibitor with an mmp inhibitor for inhibiting langerhans' cell migration |
| 01/13/2011 | US20110008357 Antibodies that bind il-18 and methods of inhibiting il-18 activity |
| 01/13/2011 | US20110008338 Treatment of Autoimmune Diseases |
| 01/13/2011 | US20110008337 Treatment of Autoimmune Diseases |
| 01/13/2011 | US20110008336 Treatment of Autoimmune Diseases |
| 01/13/2011 | US20110008330 Compositions and methods of tolerizing a primate to an antigen |
| 01/13/2011 | US20110008324 Antibody Selective for a Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Receptor and Uses Thereof |
| 01/13/2011 | US20110008307 Cephalotaxine Alkaloid Compositions and Uses Thereof |
| 01/13/2011 | US20110008278 Modulators of paraptosis and related methods |
| 01/13/2011 | US20110008250 Treatment of Autoimmune Diseases |
| 01/13/2011 | CA2767811A1 Combination therapy for the treatment of diabetes |
| 01/13/2011 | CA2765529A1 Acid pump antagonist for treatment of diseases involved in abnormal gastrointestinal motility |
| 01/13/2011 | CA2765066A1 Compositions and methods for enhancing virus efficacy |
| 01/12/2011 | EP2273419A1 Methods of treating and preventing colitis involving IL-13 and NK-T cells |
| 01/12/2011 | EP2273266A1 Parasporin-1 receptor and use thereof |
| 01/12/2011 | EP2272869A2 Angiopoietin-2 specific binding agents |
| 01/12/2011 | EP2272825A2 N-Protected amino hydroxy adamantane carboxylic acid and process for its preparation |
| 01/12/2011 | EP2272535A1 The use of anabolic agents, anti-catabolic agents, antioxidant agents, and analgesics for protection, treatment and repair of connective tissues in humans and animals |
| 01/12/2011 | EP2272529A2 DNA vaccine combined with an inducer of tumor cell apoptosis |
| 01/12/2011 | EP2272528A2 DNA vaccine combined with an inducer of tumor cell apoptosis |
| 01/12/2011 | EP2272527A2 Combined DNA vaccine and biological modifiers for cancer therapy |
| 01/12/2011 | EP2272518A1 Hypotensive lipid (prostaglandin derivatives) and timolol compositions and methods of using same |
| 01/12/2011 | EP2272516A2 4-Oxoquinoline compound and use thereof as HIV integrase inhibitor |
| 01/12/2011 | EP2272515A1 Novel uses of sodium 4-phenylbutyrate (4 pba) and the pharmaceutically acceptable salts thereof |
| 01/12/2011 | EP2272513A1 Pharmaceutical compositions for treating cancer |
| 01/12/2011 | EP2272512A1 Pharmaceutical compositions for treating cancer |
| 01/12/2011 | EP2272501A1 Polymorphs of sodium 4-((4-chloro-2-hydroxybenzoyl) amino) butanoate |
| 01/12/2011 | EP2271370A2 Compositions and methods for diagnosing and treating melanoma |
| 01/12/2011 | EP2271329A2 Methods, compositions, and kits for treating pain and pruritis |
| 01/12/2011 | EP2129368B1 Combination for use in the treatment of inflammatory disorders |
| 01/12/2011 | EP2004157B1 Use of gpr119 receptor agonists for increasing bone mass and for treating osteoporosis, as well as combination therapy relating thereto |
| 01/12/2011 | EP1686993B1 Virucidal activities of a composition comprising cetylpyridinium chloride and citric acid |
| 01/12/2011 | EP1401458B1 Composition consisting of phy906 and chemotherapeutic agents |
| 01/12/2011 | EP1302541B1 Method for recognizing bacterial DNA |
| 01/12/2011 | EP1254951B1 Molecule transferring device, auxiliary for molecule transferring device, and molecule transferring method |
| 01/12/2011 | CN1909928B Complexes having adjuvant activity |
| 01/12/2011 | CN1824315B Synergistic therapeutic compositions and methods |
| 01/12/2011 | CN1738595B Composition comprising a prebiotic for decreasing inflammatory process and abnormal activation of non-specific immune parameters |
| 01/12/2011 | CN1668314B Methods of treating hepatitis |
| 01/12/2011 | CN101945668A Combination of an iron chelator and an immunosuppressant and use thereof |